I[ntroduction]{.smallcaps} {#sec1-1}
==========================

Human leukocyte antigen (HLA) loci including HLA-A, -B, -C, -DR, -DQ, and -DP individually along with HLA haplotypes which are comprised HLA loci as a DNA string on one chromosome have been found to be associated with many diseases with autoimmune disorders, such as ankylosing spondylitis (AS),\[[@ref1][@ref2]\] type 1 diabetes,\[[@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9]\] inflammatory bowel disease,\[[@ref10][@ref11][@ref12]\] with strong association between HLA-B27 and AS being the typical example. HLA loci have also been reported to have impacts on acute graft-versus-host disease (aGVHD),\[[@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24]\] which is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the influences of HLA haplotypes on aGVHD have been rarely studied. Here, we aimed to further investigate the roles of HLA loci and haplotypes in predicting the susceptibility of patients to develop aGVHD. The factors that influence the risk of aGVHD with different grades or target organs may not be all the same even in the same study population.\[[@ref13][@ref25][@ref26]\] We chose intestinal aGVHD which is significant in both prevalence and mortality as study object and investigated whether HLA loci and haplotypes played roles in its occurrence. We confined our study in a group of HLA-matched sibling peripheral blood stem cell transplantation (PBSCT) recipients without *ex vivo* T-cell depletion. In addition, we took into account other essential aGVHD-related factors such as donor age, recipient age, donor-recipient sex combinations, stem cell source, and conditioning regimen. In the study, we followed up all of the patients for 6 months after HSCT ignoring some potential late aGHVD.

M[ethods]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The research was approved by the Ethics Committee of the hospital (approval number NI2015012-EC-1) in December 2015 and was performed in accordance with the *Declaration of Helsinki*.

Patients {#sec2-2}
--------

We retrospectively studied the clinical data of 345 consecutive patients undergoing first allo-PBSCT from HLA-matched sibling donors between February 2004 and June 2013 in Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The patients who died or lost to follow-up without symptoms of intestinal aGVHD within 100 days after HSCT were excluded from the study. The median age of the patients at transplantation was 36 years, ranging from 4 to 55 years. Out of the 345 patients, 207 (60%) were male and 138 (40%) were female. None of the grafts underwent *ex vivo* T-cell depletion. Patients were followed up for 6 months after HSCT. Clinical characteristics of the patients are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Clinical characteristics of patients undergoing first allo-PBSCT from HLA-matched sibling donors (*n* = 345)

  Characteristics                                    Values
  -------------------------------------------------- ------------
  Age (years), median (range)                        
   Recipient                                         36 (4--55)
   Donor                                             36 (7--60)
  Sex (male:female), *n*                             
   Recipient                                         207:138
   Donor                                             168:177
  Sex match (donor → recipient), *n* (%)             
   Male → Male                                       97 (28.1)
   Male → Female                                     71 (20.6)
   Female → Male                                     110 (31.9)
   Female → Female                                   67 (19.4)
  Diseases of patients at transplantation, *n* (%)   
   AML                                               164 (47.5)
   ALL                                               52 (15.1)
   CML                                               40 (11.6)
   MDS                                               38 (11.0)
   AA                                                35 (10.1)
   Other                                             16 (4.6)
  Conditioning regimen, *n* (%)                      
   TBI ± Cy ± other                                  74 (21.4)
   Bu ± Cy ± other                                   245 (71.0)
   Other                                             26 (7.5)
  GVHD prophylaxis, *n* (%)                          
   CsA + MTX                                         158 (45.8)
   FK506 + MTX                                       160 (46.4)
   CsA + MTX + other                                 17 (5.0)
   FK506 + MTX + other                               9 (2.6)
   CsA                                               1 (0.3)

AML: Acute myeloid leukemia; ALL: Acute lymphoid leukemia; CML: Chronic myeloid leukemia; MDS: Myelodysplastic syndrome; AA: Aplastic anemia; Bu: Busulfan; Cy: Cyclophosphamide; CsA: Cyclosporine; MTX: Methotrexate, FK506: Tacrolimus; allo-PBSCT: Allogeneic peripheral blood stem cell transplantation; HLA: Human leukocyte antigen; GVHD: Graft-versus-host disease; TBI: Total body irradiation.

Human leukocyte antigen typing {#sec2-3}
------------------------------

HLA typing was performed using polymerase chain reaction sequence specific primer method for low resolution of HLA-A, -B, and -DR loci.

Acute graft-versus-host disease definition {#sec2-4}
------------------------------------------

Diagnosis and staging of intestinal aGVHD were performed according to Seattle criteria.\[[@ref26][@ref27]\] Classification of aGVHD was based on NIH criteria.\[[@ref28]\] Classic aGVHD is defined to occur within 100 days after transplantation, and persistent, recurrent, or late aGVHD is defined to occur beyond 100 days. Possible gut aGVHD with isolated upper gastrointestinal tract symptoms of nausea, vomiting, and anorexia was not included due to the lack of histological proof.

Statistical analysis {#sec2-5}
--------------------

HLA loci and haplotypes with frequency over 5% (more than 18 positive cases in 345 patients) were manually searched. Other important known risk factors for aGVHD such as donor age, recipient age, donor-recipient sex combinations, and conditioning regimen (total body irradiation \[TBI\] or non-TBI) were also considered. Logistic regression was used to analyze the relationships between these factors and intestinal aGVHD. The factors with a *P* \< 0.10 in univariate analysis were further analyzed using stepwise multivariate analysis. The factors with *P* \< 0.05 in multivariate analyses were considered as statistically significant. The data were analyzed using SPSS version 18.0 (IBM Corp., Armonk, NY, USA).

R[esults]{.smallcaps} {#sec1-3}
=====================

Frequency of human leukocyte antigen loci and haplotypes {#sec2-6}
--------------------------------------------------------

In total, 30 HLA loci and 45 HLA haplotypes were detected in all patients, including two-locus haplotypes and three-locus haplotypes with frequency over 5%. HLA loci frequencies demonstrated Hardy--Weinberg equilibrium. HLA-A, -B, and -DR loci and their frequency are shown in [Table 2](#T2){ref-type="table"} in descending order. The frequency of HLA haplotypes (not shown in detail) varied from 18.6% (A2-DR15) to 5.2% (A24-B13).

###### 

HLA-A, -B, -DR loci and their frequency

  Items          Frequency (%)
  -------------- ---------------
  HLA-A locus    
   A2            55.1
   A11           29.3
   A24           28.1
   A30           17.4
   A33           9.6
   A1            9.6
   A3            9.6
   A31           6.4
   A26           5.2
  HLA-B locus    
   B15           29.3
   B13           24.6
   B40           23.8
   B46           14.2
   B51           12.2
   B7            9.9
   B35           8.4
   B48           8.4
   B44           8.1
   B54           6.4
   B58           6.4
  HLA-DR locus   
   DR15          32.8
   DR9           26.7
   DR7           22.6
   DR4           22.0
   DR12          20.9
   DR8           12.5
   DR14          12.2
   DR11          11.3
   DR13          9.9
   DR3           5.8

HLA: Human leukocyte antigen.

Incidence of intestinal acute graft-versus-host disease {#sec2-7}
-------------------------------------------------------

Intestinal aGVHD occurred in 67 recipients (19.4%). According to NIH criteria, 62 (18.0%) were classified as classic aGVHD and the rest 5 (1.4%) were classified as persistent, recurrent, or late aGVHD. The median occurrence time of intestinal aGVHD in all the recipients was 39 days after HSCT.

Relationships between all factors and intestinal acute graft-versus-host disease {#sec2-8}
--------------------------------------------------------------------------------

Univariate analysis showed that HLA loci A31, B48, DR12, HLA haplotypes A2-DR12, B13-DR15, B40-DR15, B46-DR9, donor age, recipient age, donor-recipient sex combinations might be associated with intestinal aGVHD with *P* \< 0.10, while conditioning regimen and other HLA loci or haplotypes had no significant associations with intestinal aGVHD (*P* \> 0.10). Multivariate analysis confirmed that HLA-A31 locus, HLA-B40-DR15 and HLA-B46-DR9 haplotype, female donor for male recipient were risk factors for intestinal aGVHD. HLA-B13-DR15 haplotype tended to decrease the risk of intestinal aGVHD while donor age tended to increase it \[[Table 3](#T3){ref-type="table"}\]. Comparisons of intestinal aGVHD incidence among these significant loci and haplotypes positive or negative patients are shown in [Table 4](#T4){ref-type="table"}.

###### 

Multivariate analysis for intestinal aGVHD

  Factors                           *OR*    95% *CI*       *P*
  --------------------------------- ------- -------------- -------
  HLA-B40-DR15                      3.133   1.250--7.857   0.015
  HLA-A31                           2.893   1.054--7.935   0.039
  HLA-B46-DR9                       2.580   1.070--6.220   0.035
  Female donor for male recipient   2.434   1.319--4.493   0.004
  HLA-DR12                          1.842   0.649--5.228   0.251
  HLA-A2-DR12                       1.088   0.326--3.636   0.891
  Donor age                         1.045   0.996--1.097   0.070
  Recipient age                     1.017   0.969--1.066   0.499
  HLA-B48                           0.401   0.089--1.817   0.236
  HLA-B13-DR15                      0.150   0.018--1.252   0.080

*OR*: Odds ratio; *CI*: Confidence interval; aGVHD: Acute graft-versus-host disease; HLA: Human leukocyte antigen.

###### 

Incidence of intestinal aGVHD in valuable locus/haplotype positive and negative cases

  Locus or haplotype   Present   Absent   *P*          
  -------------------- --------- -------- ----- ------ -------
  HLA-A31              22        36.4     323   18.3   0.039
  HLA-B40-DR15         32        31.3     313   18.2   0.015
  HLA-B46-DR9          32        31.3     313   18.2   0.035

aGVHD: Acute graft-versus-host disease; HLA: Human leukocyte antigen.

D[iscussion]{.smallcaps} {#sec1-4}
========================

There have been a number of studies on the association between HLA loci and aGVHD. The HLA loci such as HLA-A10, A11, A26, B18, B35, B44, B49, B50, B54, B61, Cw3, and Cw4 can increase the risk of aGVHD while HLA-Aw19, B8, Bw35, DR1, DR3, DR11, and DR15 can decrease its risk. HLA-A3 and B7 have been reported to have contrasting effects in different studies.\[[@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24]\] In our study, we found that HLA-A31 allele was a risk factor for intestinal aGVHD. There have been few researches about the influence of HLA haplotypes on aGVHD; we examined this issue and found that HLA-B40-DR15 and HLA-B46-DR9 haplotypes were risk factors for intestinal aGVHD.

HLA-A31 allele has been reported to induce restricted cytotoxic T-lymphocyte (CTL) effect in several kinds of malignant tumors such as melanoma,\[[@ref29][@ref30][@ref31]\] tumors of epithelial origin such as gastric cancer,\[[@ref32][@ref33][@ref34][@ref35][@ref36][@ref37]\] colon cancer,\[[@ref36][@ref38]\] prostate cancer,\[[@ref39][@ref40][@ref41]\] lung cancer, cervical cancer, and breast cancer,\[[@ref36][@ref41]\] viral infectious diseases or conditions associated with hepatitis B virus,\[[@ref42]\] hepatitis C virus (HCV),\[[@ref43]\] Epstein--Barr virus,\[[@ref44]\] and HIV,\[[@ref45]\] as well as rheumatoid arthritis,\[[@ref46]\] Takayasu\'s arteritis,\[[@ref47]\] Vogt--Koyanagi--Harada syndrome,\[[@ref48]\] and carbamazepine-induced adverse drug reactions.\[[@ref49]\] In addition, many of A31 restricted or presented antigens and peptides have been identified among these diseases, for example, tyrosinase-related protein in melanoma,\[[@ref29][@ref31]\] F4.2 and c98 (61--70) peptides in gastric cancer,\[[@ref32][@ref34][@ref35][@ref37]\] SART3 (109--118),\[[@ref39]\] PSA (16--24), PAP (155--163), PAP (248--257), PSMA (207--215), and PSMA (431--440) in prostate cancer,\[[@ref40]\] seven peptides (RLI 522--530, β-tublin 5154-161, β-tublin 5232-240, β-tublin 5309-317, CGI 3772-79, KIAA 0036241-248 and KIAA 0036356-363) in a set of epithelial cancers including prostate, colon, gastric, cervical, and breast cancers,\[[@ref36]\] IEX 47--56 and IEX 61--69 in epithelial cancers such as lung, prostate, cervical cancers,\[[@ref41]\] the epitope between HBcAg residues 141 and 151,\[[@ref42]\] one peptide at positions 30--39 of the core protein in HCV1b.\[[@ref43]\] HLA-A31 also plays a role in graft-versus-leukemia (GVL), which is a special case of CTL anti-tumor reaction. The cytotoxicity of CTLs generated from the bone marrow transplantation (BMT) donor lymphocytes against the patient\'s leukemic cells could be induced by a minor histocompatibility antigen (mHAg) presented with HLA-A31. CTLs that detect this mHAg may play an important role in the GVL effect in HLA-A31-positive BMT patients.\[[@ref44]\] Understanding these specific antigens or peptides would be of great value for exploring peptide-based immunotherapy against tumors or other relevant diseases. aGVHD involves a cytokine cascades where CD8+ CTLs participate at the late but essential step, with a tendency to accompanied by GVL. It is possible that in a similar way, some unknown aGVHD-specific peptides from the recipients can be presented by HLA-A31 antigen and elicit the CTL effect of aGVHD although this is just a hypothesis that needs further verification in the context of HSCT.

As to the mechanisms of how the HLA alleles affect aGVHD, two main explanations were proposed.\[[@ref18][@ref22][@ref50]\] One was that HLA molecules differ in their ability to present relevant antigens or peptides to the incoming donor-derived T cells including CD8+ and CD4+ lymphocytes. The other was that the tumor necrosis factor-α (TNF-α) gene is polymorphic and the association of TNF-α haplotype with different HLA alleles leads to different TNF-α secretion level and induces hypo- or hyper-immune reactivity. Maybe, there are certain other genes such as TAP and LMP whose gene polymorphisms also have weak associations with HLA haplotypes leading to different susceptibility to aGVHD.

Despite previous reports about the impacts of HLA loci on aGVHD, there has been only one research referring to influences of HLA haplotypes on aGVHD. Morishima *et al*.\[[@ref50]\] showed that the haplotype HLA-A\*3303-Cw\*1403-B\*4403-DRB1\*1302-DQB1\*0604-DPB1\*0401 reduced the risk of Grade 2 to 4 aGVHD, whereas HLA-A\*2402-Cw\*0702-B\*0702-DRB1\*0101-DQB1\*0501-DPB1\*0402 tended to increase the risk in allo-HSCT. We found that HLA-B40-DR15 and HLA-B46-DR9 haplotypes were risk factors for intestinal aGVHD. HLA-B46-DR9 haplotype has been found to be associated with Chinese Singaporean myasthenia gravis\[[@ref51]\] and autoimmune thyroid disease after BMT in Chinese patients.\[[@ref52]\] HLA-B40-DR15 haplotype has never been found to be associated with any diseases. In this study, we first demonstrated that this haplotype could increase the risk for intestinal aGVHD. As combinations of HLA alleles, various HLA haplotypes may display different susceptibility to aGVHD with similar mechanisms as the single locus described above (summarized in\[[@ref50]\]).

There are many factors influencing aGVHD, among which HLA parity is most important, followed by donor-recipient relationship and stem cell source. Some other factors, such as donor age, recipient age, donor-recipient sex combinations, stem cell source, conditioning regimen, and T-cell depletion, may also play roles in aGVHD. In this study, we controlled these major factors by confining the analysis to HLA-matched sibling PBSCT without *ex vivo* T-cell depletion and incorporated the crucial factors into analysis.

Nevertheless, the study still has some limitations. First, it was performed in a single center with a limited group of patients. Second, we could not detect all of the late aGVHD as we are limited to a relatively short follow-up, which might give rise to a little deviation in spite of its low incidence. Third, the study did not cover all of the gut aGVHD because the patients with isolated upper gastrointestinal aGVHD were excluded due to the lack of endoscopic biopsies. However, since most of the patients of this category usually have relatively good prognosis, they require less predictive assessments just as Grade I aGVHD was likewise usually excluded in other studies.\[[@ref25][@ref26][@ref53]\]

In conclusion, in this study, we further support the significance of HLA loci and haplotypes in aGVHD and found several valuable factors influencing intestinal aGVHD in our ethnic population. These findings may have some implications in donor selection and aGVHD prophylaxis and therapy. Due to the limited patients in a single center, the importance of these findings merits further investigation in a larger scale of population.
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